← Russell 3000 cross-section

XRAY DENTSPLY SIRONA Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$2.2bn
Revenue TTM
$3.6bn
Net income TTM
$-546m
Free cash flow
$143m
Composite score
44.5
Sector rank
#1573

Valuation

P / E
EV / EBITDA
108.2
EV / sales
1.2
FCF yield
6.40%
Earnings yield vs 10-yr
-29.15pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-15.0%
EBITDA margin
1.1%
ROE
-40.4%
ROIC
-9.3%
Revenue growth
-0.8%

Insider activity, last 90 days

Net open-market
$0.52m
Buyers
5
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Europe is also a significant market for sales of our products, including certain consumable products made in the United States, while sales in China represent less than 5% of the Company’s global sales on an annual basis. For the six months ended June 30, 2026, net sales of products produced at these sites comprised approximately 3% of our consolidated net sales and approximately 15% of the net sales of the Orthodontic and Implant Solutions segment. For the six months ended June 30, 2026, net sales in Russia and Ukraine were approximately 3% of our consolidated net sales, and net assets in these countries were $99 million as of June 30, 2026. …DENTSPLY SIRONA Inc., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →